Development and stability evaluation of extemporaneously compounded nimodipine oral suspension

Background Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological emergency often complicated by delayed cerebral ischemia. While nimodipine remains the only approved pharmacological intervention proven to improve clinical outcomes in this population, significant pharmacokinetic variability and administration challenges in dysphagic patients severely compromise its consistent clinical efficacy. Purpose To formulate an extemporaneously compounded nimodipine oral suspension and to systematically evaluate its physicochemical stability and feeding tube compatibility. Methods A compounded nimodipine suspension was prepared in 1:1 ORA-Plus® and ORA-Sweet® vehicles and stored under refrigerated and room temperature conditions for 28 days. Chemical stability was quantified via high-performance liquid chromatography (HPLC). Physical stability was evaluated by measuring pH, particle size, sedimentation volume, zeta potential, and viscosity. Administration feasibility was tested using standard enteral feeding tubes. Results The compounded formulation maintained chemical stability (90%–110% recovery) for 3 weeks refrigerated and 4 weeks at room temperature. Compared to the crude dispersion prepared by crushing tablets in water, the compounded suspension demonstrated a more negative baseline zeta potential (−21.43 ± 1.89 mV vs. −8.42 ± 2.28 mV, p < 0.001) and higher sedimentation volume (0.99 ± 0.01 vs. 0.26 ± 0.04, p < 0.001), confirming enhanced homogeneity and dispersibility. Rheological analysis confirmed a shear-thinning profile ideal for enteral delivery. Furthermore, feeding tube administration yielded >98% drug recovery without occlusion. Conclusion The compounded nimodipine suspension in this study provides a feasible alternative for enteral nimodipine administration. Future studies are needed to evaluate the formulation’s bioavailability.

Authors

Institutions

Publication Details

Journal
Journal of Pharmacy & Pharmaceutical Sciences
Published
2026-11-13
DOI
https://doi.org/10.3389/jpps.2026.17227
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and stability evaluation of extemporaneously compounded nimodipine oral suspension

Hasnaa Osama, Sherif Hanafy Mahmoud, Yifu Chu, Afsaneh Lavasanifar et al.
1 links
Journal of Pharmacy & Pharmaceutical Sciences
Pharmaceutical studies and practices
article

Development and stability evaluation of extemporaneously compounded nimodipine oral suspension

Hasnaa Osama, Sherif Hanafy Mahmoud, Yifu Chu, Afsaneh Lavasanifar, Forugh Sanaee, Adham Elshamy, Lingyun Chen, Jiangnan Hu
article en

Abstract

Background Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological emergency often complicated by delayed cerebral ischemia. While nimodipine remains the only approved pharmacological intervention proven to improve clinical outcomes in this population, significant pharmacokinetic variability and administration challenges in dysphagic patients severely compromise its consistent clinical efficacy. Purpose To formulate an extemporaneously compounded nimodipine oral suspension and to systematically evaluate its physicochemical stability and feeding tube compatibility. Methods A compounded nimodipine suspension was prepared in 1:1 ORA-Plus® and ORA-Sweet® vehicles and stored under refrigerated and room temperature conditions for 28 days. Chemical stability was quantified via high-performance liquid chromatography (HPLC). Physical stability was evaluated by measuring pH, particle size, sedimentation volume, zeta potential, and viscosity. Administration feasibility was tested using standard enteral feeding tubes. Results The compounded formulation maintained chemical stability (90%–110% recovery) for 3 weeks refrigerated and 4 weeks at room temperature. Compared to the crude dispersion prepared by crushing tablets in water, the compounded suspension demonstrated a more negative baseline zeta potential (−21.43 ± 1.89 mV vs. −8.42 ± 2.28 mV, p < 0.001) and higher sedimentation volume (0.99 ± 0.01 vs. 0.26 ± 0.04, p < 0.001), confirming enhanced homogeneity and dispersibility. Rheological analysis confirmed a shear-thinning profile ideal for enteral delivery. Furthermore, feeding tube administration yielded >98% drug recovery without occlusion. Conclusion The compounded nimodipine suspension in this study provides a feasible alternative for enteral nimodipine administration. Future studies are needed to evaluate the formulation’s bioavailability.

Journal of Pharmacy & Pharmaceutical SciencesVol. 29
Beni-Suef University (EG), University of Alberta (CA)
Good health and well-being
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon